Lentiviral RNA Integrity

Lentiviral RNA Integrity

RNA integrity analysis of the vector genome to support lentiviral vector (LVV) development and quality control: Built on Nanopore Direct RNA Sequencing (DRS), this service identifies and quantifies aberrant splicing, cryptic polyadenylation, stem-loop–associated truncations and other incompleteness events at single-molecule resolution. It reports the proportion of intact full-length RNA and the locus-level distribution of incompleteness events, providing quantitative and traceable integrity evidence for vector design optimization and quality control.

1. Background

The lentiviral vector (LVV) genome is a single-stranded RNA transcribed from the vector plasmid by RNA Polymerase II (Pol II). In addition to the transgene, this RNA carries a full complement of HIV-1–derived cis-acting elements: the 5′ and 3′ LTRs, the packaging signal Ψ, the major splice donor (MSD), the RRE, and frequently used expression-enhancing elements such as the WPRE and insulators. During production, the Pol II transcriptional machinery — combined with the dense network of splice signals, polyadenylation signals and stem-loop structures distributed across the vector RNA — means that producing a strictly full-length, intact vector RNA is not always achievable.

Incomplete vector RNA carries consequences across multiple dimensions. On the manufacturing side, incomplete RNA cannot efficiently form functional viral particles, directly lowering effective titer and raising production cost. On the efficacy side, a truncated transgene delivered into target cells may be incompletely expressed or not expressed at all, undermining therapeutic effect. On the safety side, safety elements within the vector (such as insulators) can be "spliced out" by cryptic splicing — clinical studies have linked cryptic splicing events in insulator regions to clonal expansion in patients (for example, observations in X-linked SCID gene therapy), and clonal dominance events related to the vector have likewise been observed in β-thalassemia gene therapy.

Conventional methods, however, cannot meet the requirements of integrity assessment: gel electrophoresis only indicates the approximate size distribution of RNA, and qPCR can only detect predefined local fragments. Answering the questions "what is the full-length ratio?" and "at which loci do incompleteness events occur?" requires reading each RNA molecule from end to end at single-molecule resolution.

Figure 1. Schematic of incompleteness event types and loci on lentiviral vector RNA.

Regulatory and industry guidance for vector RNA integrity analysis is well established: ICH Q5B (Analysis of the Expression Construct and Genetic Stability), Q6B (Specifications), and Q2(R2) (Validation of Analytical Procedures); the FDA guidance "CMC Information for Human Gene Therapy INDs" (2020), which incorporates vector CMC characterization into IND submission requirements; and China NMPA/CDE's "Technical Guideline for Pharmaceutical Research and Evaluation of Ex Vivo Gene-Modified Systems (Trial)" (2022), which requires clear identification of critical quality attributes (CQAs) and comprehensive method validation. This service provides CQA-grade data support along these lines through the full-length ratio and event-profile readouts.

2. Technical Principle

This service is built on Nanopore Direct RNA Sequencing (DRS), using the customer-provided full vector sequence as a custom reference for read-by-read, full-length resolution. The technical features align precisely with the requirements of vector RNA integrity assessment: native RNA is sequenced directly, eliminating reverse transcription and PCR and thereby avoiding enzymatic bias and artifacts; sequencing proceeds from the 3′ end with long-read coverage so that the 3′ end of each read corresponds to the true RNA terminus, allowing precise localization of truncations and cryptic polyA sites; splice junction relationships are reported at the single-molecule level, eliminating the ambiguity inherent in short-read assembly. The core workflow is as follows:

(1) Sample receipt and QC

Receive vector RNA (or extract RNA from vector particles), assess RNA integrity (e.g., RIN) and concentration, and confirm compliance with library construction requirements.

(2) Dual library construction (± artificial poly(A) tailing)

Direct RNA sequencing relies on a poly(A) tail for loading, yet it is precisely the tail-less truncated RNAs that warrant the closest attention. Two DRS libraries are constructed in parallel — one without artificial tailing and one with artificial tailing — so that truncated products lacking a poly(A) tail (such as stem-loop cleavage fragments and incomplete transcripts) are also captured, preventing under-detection. The current recommended chemistry, SQK-RNA004, is used to provide superior throughput and accuracy.

(3) Nanopore sequencing

Sequencing is performed on the Nanopore platform to the target depth; depth can be increased as needed to support detection of low-frequency events.

(4) Bioinformatic analysis and interpretation

Full-length alignment is performed against the customer's full vector sequence as a custom reference. Transcript isoforms are resolved read by read; aberrant splicing, cryptic polyA, and stem-loop–associated truncation events are localized; full-length ratio and per-event proportions are quantified; and an integrity analysis report is issued.

Figure 2. Workflow of the Lentiviral Vector RNA Integrity Analysis service.

3. Technical Features and Advantages

(1) Direct sequencing of native RNA

No reverse transcription and no PCR amplification — eliminating biases and artifacts introduced by enzymatic processes. What is measured reflects the true state of the RNA within the particle.

(2) Single-molecule, full-length coverage

One read covers one complete RNA molecule, directly revealing splice junction relationships and 3′-end positions at single-molecule resolution. This fills the blind spots of Sanger and short-read sequencing in resolving long RNA structures.

(3) Dual-library strategy with and without artificial tailing

The untailed library detects intact RNA together with truncated products that retain a poly(A) tail; the tailed library additionally captures truncated products without a poly(A) tail (stem-loop cleavage fragments, incomplete transcripts). The two libraries together provide comprehensive coverage of all truncation event types, preventing under-detection.

(4) Custom alignment to the client's vector

The customer-provided full vector sequence/map is used as a custom reference for read-by-read alignment. Every deviation from the design reference is reported, with conclusions that are quantitative, locus-resolved, and comparable across runs.

(5) Quantitative integrity metrics

The intact-RNA percentage and the proportion of each class of incompleteness event are translated into integrity attributes for which acceptance criteria can be defined, supporting cross-batch comparison and release-decision reference.

4. Applications

Vector design verification and optimization: Verify RNA integrity after vector construction or optimization, localize cryptic splicing/polyA/truncation sites, and guide sequence redesign and element rearrangement.

Manufacturing process change comparability: Perform integrity comparisons before and after process or supplier changes to support change-control assessment.

IND/BLA vector characterization: Provide integrity and consistency evidence on vector RNA for regulatory submissions, supporting the CMC module.

Pre-release integrity verification: Confirm vector RNA integrity before vector packaging or product release to prevent upstream errors from propagating into expensive downstream processes.

Closed-loop verification of engineering: Engineer → re-test → compare full-length ratio and event spectrum, verifying whether optimizations are effective and forming a data-driven iteration loop.

5. Report and Deliverables

The report provides quantitative, locus-resolved, comparable sequence evidence rather than a single "pass/fail" verdict. Core contents include:

·Intact RNA percentage — a key integrity metric directly comparable across batches and designs.

·Full-length transcript isoform profile and relative abundance.

·Aberrant/cryptic splicing event catalog: loci (including MSD-related sites), event type (exon skipping / intron retention / cryptic splicing) and proportions.

·3′ truncation and cryptic polyA events: loci and proportions (including frequently affected regions such as the WPRE).

·Stem-loop–associated truncation events: such as truncation at Ψ, shRNA hairpins and other structural elements, with proportions.

·Vector sequence optimization recommendations: actionable suggestions to mutate/remove cryptic sites or rearrange elements, based on event localization.

·Data deliverables: complete analysis report (PDF), event catalog/statistical files, and raw sequencing data.

·(Optional) Customized visualization analysis.

6. Service Workflow

* Standard turnaround: 40–45 business days.

7. Sample Requirements

* The latest Sample Submission Guide takes precedence. This service is not applicable to severely degraded samples. Please schedule and confirm the study plan before sample submission.

8. Technical Specifications

9. References

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products. Current Step 4 version, 30 November 1995.

[2] ICH. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Current Step 4 version, 10 March 1999.

[3] ICH. Q2(R2): Validation of Analytical Procedures. Step 4 version, adopted 1 November 2023.

[4] U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER). Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry. Final, January 2020. (Docket No. FDA-2008-D-0205)

[5] Center for Drug Evaluation, National Medical Products Administration of China (NMPA-CDE). Technical Guideline for Pharmaceutical Research and Evaluation of Ex Vivo Gene-Modified Systems (Trial) [in Chinese]. Issued 2022.